{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:37:15Z","timestamp":1762101435270},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,6,9]],"date-time":"2013-06-09T00:00:00Z","timestamp":1370736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00228-013-1529-1","type":"journal-article","created":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T07:04:35Z","timestamp":1370675075000},"page":"1785-1793","source":"Crossref","is-referenced-by-count":25,"title":["Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1"],"prefix":"10.1007","volume":"69","author":[{"given":"Christoph","family":"Markert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Marcus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,9]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010\u20133019","journal-title":"Circulation"},{"key":"1529_CR2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371:2093\u20132100","journal-title":"Lancet"},{"key":"1529_CR3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896\u2013903","journal-title":"N Engl J Med"},{"key":"1529_CR4","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2165\/00003495-200868150-00008","volume":"68","author":"JD Croxtall","year":"2008","unstructured":"Croxtall JD, Keam SJ (2008) Ambrisentan. Drugs 68:2195\u20132204","journal-title":"Drugs"},{"key":"1529_CR5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1139\/Y10-060","volume":"88","author":"JC Hartman","year":"2010","unstructured":"Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R (2010) Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 88:682\u2013691","journal-title":"Can J Physiol Pharmacol"},{"key":"1529_CR6","doi-asserted-by":"crossref","unstructured":"Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel K-D, Burhenne J, Weiss J, Mikus G, Haefeli WE (2013) Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. Br J Clin Pharmacol (in press)","DOI":"10.1111\/bcp.12177"},{"key":"1529_CR7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2010.120","volume":"88","author":"R Spence","year":"2010","unstructured":"Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R (2010) Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther 88:513\u2013520","journal-title":"Clin Pharmacol Ther"},{"key":"1529_CR8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03104.x","volume":"65","author":"RM Baldwin","year":"2008","unstructured":"Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65:767\u2013774","journal-title":"Br J Clin Pharmacol"},{"key":"1529_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","volume":"33","author":"A Hassan","year":"2011","unstructured":"Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, Czock D (2011) Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 33:86\u201393","journal-title":"Ther Drug Monit"},{"key":"1529_CR10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","volume":"64","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Hermann M, Refsum H, Molden E (2008) Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 64:1181\u20131188","journal-title":"Eur J Clin Pharmacol"},{"key":"1529_CR11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2011.127","volume":"90","author":"T Simon","year":"2011","unstructured":"Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M (2011) Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 90:287\u2013295","journal-title":"Clin Pharmacol Ther"},{"key":"1529_CR12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00228-011-1065-9","volume":"67","author":"E Aklillu","year":"2011","unstructured":"Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, K\u00f6nig S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J (2011) Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler\u00ae-based method. Eur J Clin Pharmacol 67:1139\u20131145","journal-title":"Eur J Clin Pharmacol"},{"key":"1529_CR13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 90:666\u2013673","journal-title":"Clin Pharmacol Ther"},{"key":"1529_CR14","unstructured":"US Department of Health and Human Services FDA (2001) Guidance for Industry, Bioanalytical Method Validation. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf"},{"key":"1529_CR15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/0091270009335870","volume":"49","author":"DB Richards","year":"2009","unstructured":"Richards DB, Walker GA, Mandagere A, Magee MH, Henderson LS (2009) Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 49:719\u2013724","journal-title":"J Clin Pharmacol"},{"key":"1529_CR16","first-page":"A3348","volume":"179","author":"B Harrison","year":"2009","unstructured":"Harrison B, Despain D, Mandagere A, Walker G, Dufton C (2009) Omeprazole has no clinically relevant effect on the pharmacokinetics of ambrisentan. Am J Respir Crit Care Med 179:A3348, abstract","journal-title":"Am J Respir Crit Care Med"},{"key":"1529_CR17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","volume":"35","author":"A Seithel","year":"2007","unstructured":"Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, D\u00f6rje F, Fromm MF, K\u00f6nig J (2007) The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35:779\u2013786","journal-title":"Drug Metab Dispos"},{"key":"1529_CR18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1124\/dmd.111.042267","volume":"40","author":"J Peters","year":"2012","unstructured":"Peters J, Eggers K, Oswald S, Block W, L\u00fctjohann D, L\u00e4mmer M, Venner M, Siegmund W (2012) Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. Drug Metab Dispos 40:522\u2013528","journal-title":"Drug Metab Dispos"},{"key":"1529_CR19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/11539110-000000000-00000","volume":"30","author":"B Harrison","year":"2010","unstructured":"Harrison B, Magee MH, Mandagere A, Walker G, Dufton C, Henderson LS, Boinpally R (2010) Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig 30:875\u2013885","journal-title":"Clin Drug Investig"},{"key":"1529_CR20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215\u2013236","journal-title":"Nat Rev Drug Discov"},{"key":"1529_CR21","first-page":"623","volume":"25","author":"AD Rodrigues","year":"1997","unstructured":"Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsome: major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25:623\u2013630","journal-title":"Drug Metab Dispos"},{"key":"1529_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1254\/jphs.10109FP","volume":"113","author":"J Hughes","year":"2010","unstructured":"Hughes J, Crowe A (2010) Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 113:315\u2013324","journal-title":"J Pharmacol Sci"},{"key":"1529_CR23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693\u2013705","journal-title":"Br J Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1529-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1529-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:04Z","timestamp":1558702144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1529-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,9]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1529-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,9]]}}}